Skip to main content

Table 7 Number (%) of patients with functional status and quality of life measures at baseline

From: Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation

Score Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
CGI-Severity       
N [N missing] 190 [1] 43 [0] 42 [2] 35 [0] 19 [12] 329 [15]
Extremely ill 19 (10.0%) 0 (0.0%) 3 (7.1%) 5 (14.3%) 4 (21.1%) 31 (9.4%)
Severely ill 39 (20.5%) 15 (34.9%) 3 (7.1%) 8 (22.9%) 4 (21.1%) 69 (20.9%)
Markedly ill 66 (34.7%) 18 (41.9%) 17 (40.5%) 10 (28.6%) 3 (15.8%) 114 (34.7%)
Moderately ill 45 (23.7%) 7 (16.3%) 14 (33.3%) 5 (14.3%) 4 (21.1%) 75 (22.8%)
Mildly ill 13 (6.8%) 3 (7.0%) 3 (7.1%) 4 (11.4%) 2 (10.5%) 25 (7.6%)
Borderline 4 (2.1%) 0 (0.0%) 2 (4.8%) 3 (8.6%) 1 (5.3%) 10 (3.0%)
Normal 4 (2.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.3%) 5 (1.5%)
Mean (SD) b 3.12 (1.28) 2.95 (0.90) 3.40 (1.13) 3.11 (1.49) 3.16 (1.77)  
EQ VAS       
N [N missing] 85 [106] 22 [21] 25 [19] 21 [14] 6 [25] 159 [185]
Mean (SD) b 49.5 (22.4) 42.2 (23.8) 45.6 (19.2) 50.7 (25.6) 50.5 (30.8) 48.1 (22.8)
Range 8.0-100.0 6.0-90.0 8.0-85.0 5.0-90.0 20.0-92.0 5.0-100.0
EQ-5D Index       
N [N missing] 181 [10] 43 [0] 43 [1] 34 [1] 18 [13] 319 [25]
Mean (SD) c 0.40 (0.34) 0.37 (0.37) 0.42 (0.32) 0.52 (0.39) 0.51 (0.40) 0.42 (0.35)
Range -0.24-1.00 -0.24-1.00 -0.24-0.80 -0.48-1.00 -0.35-1.00 -0.48-1.00
Disease specific HAQ Score    DLQI Score CHAQ Score  
N [N missing] 190 [1] - - 35 [0] 9 [22]  
Mean (SD) 1.74 (0.65) - - 15.0 (7.8) 1.35 (0.54)  
Range 0.00-3.00 - - 3.0-30.0 0.50-2.25  
      CHAQ Pain Score  
N [N missing] - - - - 8 [23]  
Mean (SD) - - - - 49.1 (30.1)  
Range - - - - 7.0-90.0  
  1. a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?
  2. b No significant differences in mean CGI-S or EQ-5D VAS scores between conditions using the Kruskal-Wallis test or ANOVA.
  3. c No significant differences in mean CGI-S or EQ-5D VAS scores between conditions using the Kruskal-Statistically significant differences in EQ-5D Index scores between the conditions using the Kruskal-Wallis test (p = 0.043), but not with ANOVA, p = 0.259.
  4. CHAQ Child Health Assessment Questionnaire (for patients with juvenile idiopathic arthritis), CGI Clinical Global Impression, DLQI Dermatology Life Quality Index (for patients with psoriasis), EQ EuroQoL, HAQ Health Assessment Questionnaire (for patients with rheumatoid arthritis), VAS Visual analogue scale